April 11, 2019 11:06 AM EDT
News Briefing

Cam­brex com­pletes $24M API man­u­fac­tur­ing fa­cil­i­ty; Twist and LakePhar­ma part­ner on an­ti­body con­tract work

John Carroll

Editor & Founder

→ Cam­brex Cor­po­ra­tion $CBM com­plet­ed its $24 mil­lion API (HPA­PI) man­u­fac­tur­ing fa­cil­i­ty at its site in Charles City, IA. The fa­cil­i­ty is un­der­go­ing val­i­da­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times